166 related articles for article (PubMed ID: 35567637)
1. Lung cancer metabolomic data from tumor core biopsies enables risk-score calculation for progression-free and overall survival.
Miller HA; Rai SN; Yin X; Zhang X; Chesney JA; van Berkel VH; Frieboes HB
Metabolomics; 2022 May; 18(5):31. PubMed ID: 35567637
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer survival prediction and biomarker identification with an ensemble machine learning analysis of tumor core biopsy metabolomic data.
Miller HA; van Berkel VH; Frieboes HB
Metabolomics; 2022 Jul; 18(8):57. PubMed ID: 35857204
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data.
Miller HA; Yin X; Smith SA; Hu X; Zhang X; Yan J; Miller DM; van Berkel VH; Frieboes HB
Lung Cancer; 2021 Jun; 156():20-30. PubMed ID: 33882406
[TBL] [Abstract][Full Text] [Related]
4. Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer.
Wang NF; Tang HM; Liu FL; Hong QY
Chin Med J (Engl); 2020 Apr; 133(7):786-791. PubMed ID: 32195672
[TBL] [Abstract][Full Text] [Related]
5. Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma.
Evers PD; Logan JE; Sills V; Chin AI
World J Urol; 2014 Apr; 32(2):385-91. PubMed ID: 23756991
[TBL] [Abstract][Full Text] [Related]
6. Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
Zhuang J; Tang X; Du Z; Yang M; Zhou Y
Talanta; 2016 Nov; 160():636-644. PubMed ID: 27591660
[TBL] [Abstract][Full Text] [Related]
7. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
8. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Zanotti R; Perkins C; Jawhar M; Sperr WR; Shoumariyeh K; Schwaab J; Greiner G; Henriques A; Caldas C; Fernández-Giménez C; Sánchez-Muñoz L; Mayado A; Pérez-Pons A; Schmitt-Graeff A; Duyster J; Tanasi I; Olivieri F; Mora-Casterá E; Luna I; Senent L; Bañas MH; Nuñez-García A; Jurado-Chacón M; Martín-Sánchez G; Colado E; Xicoy B; Gener-Ricós G; Gotlib J; Bonadonna P; Reiter A; Valent P; García-Montero AC; Orfao A
Lancet Haematol; 2021 Mar; 8(3):e194-e204. PubMed ID: 33508247
[TBL] [Abstract][Full Text] [Related]
9. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
10. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
[TBL] [Abstract][Full Text] [Related]
11. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer.
Liu X; Hou Y; Wang X; Yu L; Wang X; Jiang L; Yang Z
Hepatol Int; 2020 Jul; 14(4):567-576. PubMed ID: 32556865
[TBL] [Abstract][Full Text] [Related]
12. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity.
Luo Y; Feng B; Wei D; Han Y; Li M; Zhao J; Lin Y; Hou Z; Jiang Y
Sci Rep; 2020 Oct; 10(1):17674. PubMed ID: 33077839
[TBL] [Abstract][Full Text] [Related]
14. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
15. Plasma metabolomics for the assessment of the progression of non-small cell lung cancer.
Zhang Y; Cheng Y; Qin L; Liu Y; Huang S; Dai L; Tao J; Pan J; Su C; Zhang Y
Int J Biol Markers; 2023 Mar; 38(1):37-45. PubMed ID: 36377344
[TBL] [Abstract][Full Text] [Related]
16. Development of a metabolite calculator for diagnosis of pancreatic cancer.
Choi M; Park M; Lee SH; Lee MJ; Paik YK; Jang SI; Lee DK; Lee SG; Kang CM
Cancer Med; 2023 Aug; 12(15):15933-15944. PubMed ID: 37350558
[TBL] [Abstract][Full Text] [Related]
17. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
[TBL] [Abstract][Full Text] [Related]
18. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
